UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.42 USD
+0.02 (1.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $1.40 -0.02 (-1.41%) 7:18 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.42 USD
+0.02 (1.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $1.40 -0.02 (-1.41%) 7:18 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
by Zacks Equity Research
UNITY Biotechnology (UBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Unity (UNX) Down on Disappointing Results From Wet AMD Study
by Zacks Equity Research
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
by Zacks Equity Research
UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
by Zacks Equity Research
UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.
Unity Biotechnology (UBX) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study
by Zacks Equity Research
Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.
Moving Average Crossover Alert: Unity Biotechnology
by Zacks Equity Research
Unity Biotechnology, Inc. (UBX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Unity Biotechnology Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Unity Biotechnology
Unity Biotechnology's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Unity Biotechnology.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
by Swarup Gupta
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
UNITY (UBX) Soars: Stock Adds 5.1% in Session
by Zacks Equity Research
UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Unity (UBX) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for August 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 16th: